Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy…
News
Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex (daratumumab) in patients with multiple…
MYELOMA
Non-profit Cancer Therapy Consultant Patient Power Praises District of Columbia Law Limiting Co-pays
The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma.
The International Myeloma Foundation (IMF) says it is deeply worried that the American Health Care Act (AHCA) — which narrowly passed the U.S. House of…
A new documentary, “200 Miles,” tells the inspiring story of ultra-marathoner Eric Gelber’s determination to complete 33 loops of New York’s Central Park to…
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food…
MYELOMA
One World Cannabis to Test Mice in Pursuit of Therapies Targeting Multiple Myeloma Cancer Cells
Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results…
Janssen’s Darzalex (daratumumab) received full approval by the European Commission (EC) for use in treating adult patients with multiple myeloma who have received at least…
GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients who failed to respond to…
Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened…
Recent Posts
- ‘Unprecedented’ response seen with narmafotinib in pancreatic cancer trial
- As a cancer caregiver, I am the ‘lightning rod’ that absorbs the storm
- Myosin wins $2M grant to advance brain cancer treatment MT-125
- Overt forms advisory board to guide ovarian cancer therapy push
- CAR T-cell therapy moving to frontline as myeloma treatment
